. . . . "PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Medication Guide). 17.1 Rash Prior to initiation of treatment with lamotrigine extended-release tablets, the patient should be instructed that a rash or other signs or symptoms of hypersensitivity (e.g., fever, lymphadenopathy) may herald a serious medical event and that the patient should report any such occurrence to a physician i" .